Sera Prognostics (NASDAQ:SERA – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Earnings & Valuation
This table compares Sera Prognostics and Longeveron”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $80,000.00 | 1,030.63 | -$31.93 million | ($0.67) | -3.12 |
| Longeveron | $1.20 million | 6.86 | -$22.70 million | ($9.90) | -0.26 |
Volatility and Risk
Sera Prognostics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for Sera Prognostics and Longeveron, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 163.16%. Longeveron has a consensus price target of $80.00, indicating a potential upside of 3,000.78%. Given Longeveron’s higher probable upside, analysts clearly believe Longeveron is more favorable than Sera Prognostics.
Institutional and Insider Ownership
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Sera Prognostics and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
Summary
Sera Prognostics beats Longeveron on 9 of the 14 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
